Research programme: macular degeneration therapy - Columbia University/MultiCell TechnologiesAlternative Names: MCT-355
Latest Information Update: 08 Jun 2010
At a glance
- Originator Columbia University; MultiCell Technologies Inc
- Class Small molecules
- Mechanism of Action Apoptosis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Macular degeneration
Most Recent Events
- 12 Dec 2005 Preclinical trials in Macular degeneration in USA (unspecified route)